Publicaciones en colaboración con investigadores/as de Sociedad Española de Reumatología (37)

2024

  1. Early identification of golimumab-treated patients with higher likelihood of long-term retention

    Frontiers in Immunology, Vol. 15

  2. Management, development and methodology of the Clinical Practice Guidelines and Recommendations of the Spanish Society of Rheumatology

    Reumatologia Clinica, Vol. 20, Núm. 7, pp. 392-397

  3. Real-world persistence of initial targeted therapy strategy in monotherapy versus combination therapy in patients with chronic inflammatory arthritis

    European Journal of Clinical Investigation, Vol. 54, Núm. 2

2023

  1. Development of a web tool to calculate the cumulative dose of glucocorticoids

    Reumatologia Clinica, Vol. 19, Núm. 1, pp. 1-5

  2. Effects of COVID-19 vaccination on disease activity in patients with rheumatoid arthritis and psoriatic arthritis on targeted therapy in the COVIDSER study

    RMD open, Vol. 9, Núm. 1

  3. Four-years retention rate of golimumab administered after discontinuation of non-TNF inhibitors in patients with inflammatory rheumatic diseases

    Advances in Rheumatology, Vol. 63, Núm. 1

  4. Long-term retention of golimumab treatment in clinical practice in a large cohort of patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis

    Musculoskeletal Care, Vol. 21, Núm. 1, pp. 189-197

2022

  1. Prevalence of gout in the adult general population in Spain: Estimating the proportion of undiagnosed cases

    Joint Bone Spine, Vol. 89, Núm. 1

  2. Prevalence of symptomatic axial osteoarthritis phenotypes in Spain and associated socio-demographic, anthropometric, and lifestyle variables

    Rheumatology International, Vol. 42, Núm. 6, pp. 1085-1096

  3. The reality of Rheumatology in Spain and its autonomous communities before the pandemic

    Reumatologia Clinica, Vol. 18, Núm. 8, pp. 486-489

2021

  1. Comment on: Prevalence of systemic lupus erythematosus in Spain: higher than previously reported in other countries? Reply

    Rheumatology (Oxford, England), Vol. 60, Núm. 3, pp. e120-e121

  2. Factors associated with long-term retention of treatment with golimumab in rheumatoid arthritis, axial spondyloarthritis, and psoriatic arthritis: an analysis of the Spanish BIOBADASER registry

    Clinical Rheumatology, Vol. 40, Núm. 10, pp. 3979-3988

  3. Prevalence of symptomatic osteoarthritis in Spain: EPISER2016 study

    Reumatologia Clinica, Vol. 17, Núm. 8, pp. 461-470

  4. Role of targeted therapies in rheumatic patients on COVID-19 outcomes: Results from the COVIDSER study

    RMD Open, Vol. 7, Núm. 3

2020

  1. Association between periodontitis and anti-citrullinated protein antibodies in rheumatoid arthritis patients: A cross-sectional study

    Arthritis Research and Therapy, Vol. 22, Núm. 1

  2. Fracture risk assessment in the general population in Spain by FRAX® algorithm. EPISER2016 study

    Medicina Clinica, Vol. 154, Núm. 5, pp. 163-170

  3. Higher prevalence of psoriatic arthritis in the adult population in Spain? A population-based cross-sectional study

    PLoS ONE, Vol. 15, Núm. 6

  4. Prevalence of Sjögren’s syndrome in the general adult population in Spain: estimating the proportion of undiagnosed cases

    Scientific Reports, Vol. 10, Núm. 1

  5. Prevalence of ankylosing spondylitis in Spain: EPISER2016 Study

    Scandinavian Journal of Rheumatology, Vol. 49, Núm. 3, pp. 210-213

  6. Prevalence of fibromyalgia and associated factors in Spain

    Clinical and experimental rheumatology, Vol. 38, Núm. 1, pp. 47-52